Survodutide half-life & pharmacokinetics

Reported half-life

Approximately 168 hours (~7 days) plasma half-life through fatty-acid acylation, supporting once-weekly subcutaneous dosing similar to semaglutide, tirzepatide, and retatrutide.

The half-life and pharmacokinetic profile of Survodutide reported above is drawn from the published pre-clinical literature. Plasma half-life describes the time taken for the circulating concentration to fall by half after a single dose; tissue half-life — which may be longer for peptides retained in specific organs or matrices — is a distinct and often more relevant parameter for healing research, where the duration of exposure at the injury site matters more than the systemic exposure profile.

Routes of administration studied

• Subcutaneous injection (Phase III clinical trial route; not licensed)

Different routes produce materially different pharmacokinetic profiles for the same peptide. Subcutaneous administration generally produces flatter, more sustained plasma profiles than intravenous bolus dosing; intraperitoneal administration (common in rodent models) is not directly translatable to human routes; oral administration faces the additional challenge of luminal and brush-border peptidase degradation, which is why most research peptides have very low oral bioavailability without protective formulation.

Drug class

Dual GLP-1 / glucagon receptor agonist; Phase III clinical-development unlicensed compound.

Mechanism context

Half-life interpretation depends on the underlying mechanism. Survodutide acts as follows:

Survodutide (Boehringer Ingelheim development code BI 456906, originally Zealand Pharma) is a dual GLP-1 receptor and glucagon receptor agonist — engaging both incretin (GLP-1R) and counter-regulatory (glucagon-R) pharmacology in a single molecule. The two-receptor mechanism is architecturally intermediate between semaglutide (GLP-1R monoagonist), tirzepatide (GLP-1R/GIPR dual agonist), and retatrutide (GLP-1R/GIPR/glucagon-R triple agonist). Survodutide's specific innovation is the GLP-1 + glucagon combination without GIPR involvement.

See the full Survodutide research profile for the complete mechanism summary, history, study citations, and references.

Practical considerations

Short plasma half-life does not necessarily mean short duration of biological effect. Many peptides — including BPC-157, GHK-Cu, and the thymosin-derived compounds — exhibit tissue retention or mechanistic effects (gene expression, signalling cascades) that outlast plasma exposure by hours to days. The pharmacological half-life and the biological-effect half-life are distinct parameters that must both be specified in any rigorous research design. Repeated-dose protocols should account for accumulation only where tissue half-life is genuinely long; for most peptides with short plasma half-life and rapid degradation, accumulation is not a practical concern.

For dose ranges in published research, see the dosing reference page. For reconstitution guidance, see the reconstitution reference page.